2022
Effect of Implementation Facilitation to Promote Adoption of Medications for Addiction Treatment in US HIV Clinics
Edelman EJ, Gan G, Dziura J, Esserman D, Porter E, Becker WC, Chan PA, Cornman DH, Helfrich CD, Reynolds J, Yager JE, Morford KL, Muvvala SB, Fiellin DA. Effect of Implementation Facilitation to Promote Adoption of Medications for Addiction Treatment in US HIV Clinics. JAMA Network Open 2022, 5: e2236904. PMID: 36251291, PMCID: PMC9577676, DOI: 10.1001/jamanetworkopen.2022.36904.Peer-Reviewed Original ResearchConceptsTobacco use disorderHIV clinicOpioid use disorderUse disordersAlcohol use disorderAddiction treatmentControl periodImplementation facilitationAdoption of medicationsMulticomponent implementation strategyProvision of MOUDUS HIV clinicsMaintenance periodElectronic health record dataHealth record dataEvaluation periodAdult patientsMean ageClinical trialsMAIN OUTCOMEClinicMOUDPatientsDisordersPatient incentives
2021
Maternal opioid use disorder: Placental transcriptome analysis for neonatal opioid withdrawal syndrome
Radhakrishna U, Nath SK, Vishweswaraiah S, Uppala LV, Forray A, Muvvala SB, Mishra NK, Southekal S, Guda C, Govindamangalam H, Vargas D, Gardella WG, Crist RC, Berrettini WH, Metpally RP, Bahado-Singh RO. Maternal opioid use disorder: Placental transcriptome analysis for neonatal opioid withdrawal syndrome. Genomics 2021, 113: 3610-3617. PMID: 34352367, DOI: 10.1016/j.ygeno.2021.08.001.Peer-Reviewed Original ResearchConceptsNeonatal opioid withdrawal syndromeOpioid withdrawal syndromeWithdrawal syndromePrenatal opioid exposureOpioid use disorderPlacentas of infantsPlacental tissue samplesP-valueIngenuity Pathway AnalysisOpioid exposureUse disordersUnexposed controlsFDR p-valueGenes CYP1A1Tissue samplesSyndromePathway analysisCYP1A1NewbornsInfantsEtiologyApoBPlacentaGenesGRIN2AThe effect of varenicline on smoking and drinking outcomes among Black and White adults with alcohol use disorder and co-occurring cigarette smoking: A secondary analysis of two clinical trials
Haeny AM, Gueorguieva R, Montgomery L, Bold KW, Fucito LM, Wu R, Muvvala SB, Zweben A, O'Malley SS. The effect of varenicline on smoking and drinking outcomes among Black and White adults with alcohol use disorder and co-occurring cigarette smoking: A secondary analysis of two clinical trials. Addictive Behaviors 2021, 122: 106970. PMID: 34216871, PMCID: PMC9426655, DOI: 10.1016/j.addbeh.2021.106970.Peer-Reviewed Original ResearchConceptsEffects of vareniclineAlcohol use disorderCigarette smokingClinical trialsUse disordersWhite adultsEfficacy of vareniclineNumber of drinksVareniclineSmokingPrimary analysisAlcohol treatmentSecondary analysisAlcohol useTrialsBlack participantsDrinking outcomesLinear mixed modelsAdultsWhite peopleWhite participantsMixed modelingCigarettesDisordersTreatmentPlacental DNA methylation profiles in opioid-exposed pregnancies and associations with the neonatal opioid withdrawal syndrome
Radhakrishna U, Vishweswaraiah S, Uppala LV, Szymanska M, Macknis J, Kumar S, Saleem-Rasheed F, Aydas B, Forray A, Muvvala SB, Mishra NK, Guda C, Carey DJ, Metpally RP, Crist RC, Berrettini WH, Bahado-Singh RO. Placental DNA methylation profiles in opioid-exposed pregnancies and associations with the neonatal opioid withdrawal syndrome. Genomics 2021, 113: 1127-1135. PMID: 33711455, DOI: 10.1016/j.ygeno.2021.03.006.Peer-Reviewed Original ResearchConceptsNeonatal opioid withdrawal syndromeOpioid withdrawal syndromeIngenuity Pathway AnalysisWithdrawal syndromeOpioid-exposed pregnanciesPlacental tissue samplesOpioid abusePlacental tissueTissue samplesPregnancyMethylation dysregulationGenome-wide methylation analysisSyndromeInfantsPathway analysisAUCDNA methylation profilesMethylation profilesGroupPathophysiologyTherapyStrong evidence
2020
Multiple Psychiatric Morbidity and Continued Use of Naltrexone for Alcohol Use Disorder
Muvvala SB, O'Malley SS, Rosenheck R. Multiple Psychiatric Morbidity and Continued Use of Naltrexone for Alcohol Use Disorder. American Journal On Addictions 2020, 30: 55-64. PMID: 32805083, DOI: 10.1111/ajad.13089.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAlcohol DeterrentsAlcoholismAmbulatory CareDepressive Disorder, MajorFemaleHospitalizationHumansIll-Housed PersonsMaleMental Health ServicesMiddle AgedMorbidityNaltrexonePsychotherapyPsychotropic DrugsSchizophreniaSocioeconomic FactorsUnited StatesUnited States Department of Veterans AffairsVeteransConceptsAlcohol use disorderUse of naltrexonePsychotropic prescription fillsPrescription fillsUse disordersOutpatient mental health servicesCorrelates of initiationMedical-surgical hospitalizationMultiple psychiatric morbiditiesEfficacy of naltrexonePsychotropic medication useVeterans Health AdministrationPsychiatric outpatient servicesConcurrent psychiatric disordersMajor depressive disorderMental health servicesProportion of veteransNaltrexone initiationMedication usePsychiatric morbidityDepressive disorderImportant patientPsychiatric hospitalizationMultinomial logistic regressionOutpatient servicesEffects of Alcohol Cue Reactivity on Subsequent Treatment Outcomes Among Treatment‐Seeking Individuals with Alcohol Use Disorder: A Multisite Randomized, Double‐Blind, Placebo‐Controlled Clinical Trial of Varenicline
Miranda R, O’Malley S, Padovano H, Wu R, Falk DE, Ryan ML, Fertig JB, Chun TH, Muvvala SB, Litten RZ. Effects of Alcohol Cue Reactivity on Subsequent Treatment Outcomes Among Treatment‐Seeking Individuals with Alcohol Use Disorder: A Multisite Randomized, Double‐Blind, Placebo‐Controlled Clinical Trial of Varenicline. Alcohol Clinical And Experimental Research 2020, 44: 1431-1443. PMID: 32363592, PMCID: PMC7572549, DOI: 10.1111/acer.14352.Peer-Reviewed Original ResearchConceptsAlcohol use disorderEffects of vareniclineAlcohol cue reactivityClinical trialsCue-reactivity paradigmAlcohol useCue reactivityUse disordersHuman laboratoryAlcohol cue-induced cravingSubsequent treatment outcomesΑ4β2 nicotinic acetylcholine receptorsCue-induced alcoholAlcohol cue reactivity paradigmCue-induced cravingNicotinic acetylcholine receptorsHeavy alcohol useCue-elicited cravingHuman laboratory paradigmTreatment outcomesVareniclinePlaceboProspective associationsAlcohol cravingAcetylcholine receptors
2019
Longitudinal Findings from a Randomized Clinical Trial of Varenicline for Alcohol Use Disorder with Comorbid Cigarette Smoking
Bold KW, Zweben A, Fucito LM, Piepmeier ME, Muvvala S, Wu R, Gueorguieva R, O'Malley SS. Longitudinal Findings from a Randomized Clinical Trial of Varenicline for Alcohol Use Disorder with Comorbid Cigarette Smoking. Alcohol Clinical And Experimental Research 2019, 43: 937-944. PMID: 30817018, PMCID: PMC7039307, DOI: 10.1111/acer.13994.Peer-Reviewed Original ResearchConceptsEnd of treatmentAlcohol use disorderHeavy drinking daysMedical managementCigarette smokingComorbid cigarette smokingUse disordersDrinking daysCo-occurring alcohol use disorderHigh ratePlacebo-controlled trialBetter clinical outcomesAssessment of alcoholPercent of participantsVarenicline treatmentClinical outcomesSmoking abstinenceParallel groupClinical trialsTimeline FollowVareniclineSmoking behaviorAlcohol treatmentPosttreatment outcomesMultisite trial
2018
Randomized Clinical Trial of Computerized and Clinician-Delivered CBT in Comparison With Standard Outpatient Treatment for Substance Use Disorders: Primary Within-Treatment and Follow-Up Outcomes
Kiluk BD, Nich C, Buck MB, Devore KA, Frankforter TL, LaPaglia DM, Muvvala SB, Carroll KM. Randomized Clinical Trial of Computerized and Clinician-Delivered CBT in Comparison With Standard Outpatient Treatment for Substance Use Disorders: Primary Within-Treatment and Follow-Up Outcomes. American Journal Of Psychiatry 2018, 175: 853-863. PMID: 29792052, PMCID: PMC6120780, DOI: 10.1176/appi.ajp.2018.17090978.Peer-Reviewed Original ResearchConceptsCognitive behavioral therapySubstance use disordersComputer-based cognitive behavioral therapyUse disordersMinimal clinical monitoringTreatment-seeking populationTreatment-seeking outpatientsDSM-IV-TR criteriaCBT groupFrequency of substanceStandard outpatient careCBT4CBTStand-alone treatmentDiverse sampleStandard outpatient treatmentCurrent substance use disorderBehavioral conceptsBetter learningSubstance abuseHeterogeneous sampleUp OutcomesHigh dropout ratePrevious trialsSix-month followClinical trialsEffect of Varenicline Combined With Medical Management on Alcohol Use Disorder With Comorbid Cigarette Smoking: A Randomized Clinical Trial
O’Malley S, Zweben A, Fucito LM, Wu R, Piepmeier ME, Ockert DM, Bold KW, Petrakis I, Muvvala S, Jatlow P, Gueorguieva R. Effect of Varenicline Combined With Medical Management on Alcohol Use Disorder With Comorbid Cigarette Smoking: A Randomized Clinical Trial. JAMA Psychiatry 2018, 75: 129-138. PMID: 29261824, PMCID: PMC5838706, DOI: 10.1001/jamapsychiatry.2017.3544.Peer-Reviewed Original ResearchConceptsAlcohol use disorderMedical managementUse disordersCigarette smokingWeek 9Varenicline tartrateEfficacy of vareniclinePlacebo-controlled trialBehavioral health risksComorbid cigarette smokingRace/ethnicityAlcohol dependence criteriaSmoking 2Medication adherenceOutpatient clinicPlacebo pillsMean ageEligible participantsSmoking abstinenceClinical trialsParallel groupPlaceboMAIN OUTCOMEVareniclineWeek 13